Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15135077 | 0.83 | TAS1R3 (0.30) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5421024 | 0.80 | ALDH1A1 (0.30) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL31272969 | 0.79 | — | — | |
| SCHEMBL14994991 | 0.76 | — | — | |
| SCHEMBL26110875 | 0.74 | CRHR1 (0.33) | — | |
| SCHEMBL23087149 | 0.71 | HRH3 (0.33) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL5471894 | 0.69 | ALDH1A1 (0.30) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL30142129 | 0.69 | ALDH1A1 (0.31) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL23087150 | 0.68 | ALDH1A1 (0.35) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL727932 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669330-B2 | Olefin triblock polymers via ring-opening metathesis polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-8283419-B2 | Olefin functionalization by metathesis reaction | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-10-09 | — | — | US | claimed |
| US-20240140946-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-05-02 | — | — | US | disclosed |
| US-11884662-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2024015412-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023127582-A1 | POLYMER, METHOD FOR PRODUCING SAME, RESIN COMPOSITION, AND ELECTRONIC COMPONENT | 日本ゼオン株式会社 | 2023-07-06 | — | — | WO | disclosed |
| US-11565511-B2 | Co-injection molded multilayer structure and method for producing same | KURARAY CO., LTD. (JP) | 2023-01-31 | — | — | US | disclosed |
| EP-3802536-B1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11383497-B2 | Co-injection-molded multilayer structure | KURARAY CO., LTD. (JP) | 2022-07-12 | — | — | US | disclosed |
| US-11332496-B2 | Stapled and stitched polypeptides and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3428203-B1 | HYDROCARBON POLYMERS WITH ALKOXYSILANE TERMINAL GROUP | BOSTIK SA (FR) | 2022-04-27 | — | — | EP | disclosed |
| US-20060258828-A1 | Polymerizable composition and molded articles produced by using the same | ZEON CORPORATION (JP) | 2006-11-16 | — | — | US | disclosed |
| US-20060211834-A1 | Method of manufacturing thermoplastic resin, crosslinked resin, and crosslinked resin composite material | ZEON CORPORATION (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20060205901-A1 | Crosslinkable resin composition and resin formed body produced therefrom | ZEON CORPORATION (JP) | 2006-09-14 | — | — | US | disclosed |
| US-20060154099-A1 | Multilayer body and method for producing same | ZEON CORPORATION (JP) | 2006-07-13 | — | — | US | disclosed |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-07-06 | — | — | US | disclosed |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | VICURON PHARMACEUTICALS INC. | 2005-09-29 | — | — | US | disclosed |
| EP-1535941-A1 | PROCESSES FOR PRODUCING THERMOPLASTIC RESINS, CROSSLINKED RESINS AND CROSSLINKED RESIN COMPOSITE MATERIALS | ZEON CORPORATION (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2001072421-A1 | POLYMER SUPPORTED CATALYSTS FOR OLEFIN METATHESIS | GLAXO GROUP LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884662-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, CCL5 | ALDH1A1 773/4885POLB 939/4885MAPT 4615/4885 |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | LCLAT1, LAS1L, NRDC | ALDH1A1 2927/4885POLB 2163/4885MAPT 4511/4885 |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PAM, MLYCD, PPT1 | ALDH1A1 2254/4885POLB 3052/4885MAPT 4240/4885 |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | LCLAT1, NRDC, LAS1L | ALDH1A1 2991/4885POLB 2201/4885MAPT 4461/4885 |
| US-11332496-B2 | Stapled and stitched polypeptides and uses thereof | VIP, NGLY1, IAPP | ALDH1A1 4451/4885POLB 1366/4885MAPT 3000/4885 |
| US-20240140946-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, CCL5 | ALDH1A1 1543/4885POLB 877/4885MAPT 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.